ESMO 2021: Cabozantinib for collecting duct carcinoma – the BONSAI study

Metastatic collecting duct carcinoma is an aggressive form of RCC, which is poorly researched and understood. There is an unmet need for an effective treatment for these patients, and very few clinical trials allow these patients to take part. This single centre, phase 2 trial tested cabozantinib in untreated patients with collecting duct carcinoma that […]

read more

Atezolizumab and bevacizumab for non-clear cell renal cell carcinoma

In this video interview from Practice Update, Dr Brad McGregor from Dana-Faber Cancer Institute in Boston, USA, talks about the results from a phase 2 trial with the combination of atezolizumab plus bevacizumab in patients with metastatic non-clear cell renal cell carcinoma (RCC). The study enrolled 60 patients, 42 of which had non-clear cell RCC […]

read more
Showing all 2 results